Using digital tools to monitor mobility in neuromuscular patients
Feasibility, Validation and Application of Digital Tools for the Follow-up of Neuromuscular Patient
NA · Institut de Myologie, France · NCT05798325
This study is testing digital tools to track how well young people and adults with neuromuscular diseases move in their daily lives to help improve future treatments.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 12 Years to 60 Years |
| Sex | All |
| Sponsor | Institut de Myologie, France (other) |
| Locations | 2 sites (Paris and 1 other locations) |
| Trial ID | NCT05798325 on ClinicalTrials.gov |
What this trial studies
This study aims to integrate and validate digital tools for monitoring the mobility of patients with neuromuscular diseases in their daily lives. By utilizing objective measures such as accelerometers, the study seeks to distinguish between different types of movements and improve the assessment of patient mobility. The goal is to enhance the design of clinical trials by providing high-quality, reproducible data that can support the development of new treatments. The study will involve patients aged 12 to 60 with confirmed neuromuscular conditions who experience walking difficulties.
Who should consider this trial
Good fit: Ideal candidates are patients aged 12 to 60 with genetically confirmed neuromuscular or neurometabolic diseases who have walking difficulties.
Not a fit: Patients with undefined diagnoses or those who can walk 10 meters in less than 10 seconds may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and treatment options for patients with neuromuscular diseases.
How similar studies have performed: Other studies have shown success in using digital tools for monitoring patient mobility, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged between 12 and 60 years * Patients with a genetically confirmed/molecular-proven neuromuscular or neurometabolic disease\* * Patients experiencing walking difficulties in the home and at high risk of limiting participation and walking outside of the home. * Written informed consent * Able to comply with all protocol requirements, including video recording * Affiliated to or beneficiary of a social security scheme (for France) Exclusion Criteria: * Patients with undefined diagnosis or any diagnosis other than neuromuscular or neurometabolic disease * Patient walking 10m in less than 10s * Guardianship/trusteeship * Pregnant or nursing women * Patients having relevant concomitant pathologies that, in the appreciation of the investigator could interfere with protocol compliance * Patients not being affiliated with local social security (for France)
Where this trial is running
Paris and 1 other locations
- Association Institut de Myologie — Paris, France (RECRUITING)
- John Walton Muscular Dystrophy Research Centre — Newcastle Upon Tyne, United Kingdom (NOT_YET_RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neuromuscular Diseases, Dystrophy, Monitoring, Accelerometer, Evaluation